


Background

- The histopathology of sebaceous carcinoma (SBC) can mimic other skin neoplasms, including basal cell carcinoma (BCC). Therefore, diagnostic biomarkers are needed for a subset of cases.
- Normal sebaceous glands express PRAME (PRAME nuclear receptor transcriptional regulator), a melanoma-associated biomarker.



Sebaceous glands (H&E stain and PRAME stain)

- Donell et al. showed that PRAME has strong immunoreactivity with basaloid sebocytes in SBC.
- Ng et al. reported patchy cytoplasmic staining in the germinative sebocytes only.

Objective

 To evaluate the utility of PRAME immunohistochemistry as a diagnostic biomarker for SBC and its usefulness in the distinction of SBC from BCC.

Methodology

- The institutional dermatopathology database was searched and 19 SBCs and 42 nodular BCCs were selected.
- Formalin-fixed, paraffin-embedded tissue blocks were cut and stained with H&E and PRAME antibody.
- Tumors were independently scored for PRAME expression by two authors (MFOS and MSD) using consensus scoring.
- Scores were based on the extent of staining (percent of positive cells), staining pattern (diffuse/focal/patchy), intensity (weak/moderate/strong), and subcellular location (nuclear/cytoplasmic).

Diagnosis		Age	Sex		Location		
	N	Median	F	Μ	Head & Neck	Trunk	Extremity
Sebaceous Carcinoma	19	70 (48-90)	9	10	9	4	6
Basal Cell Carcinoma,							
Nodular	42	71 (44-94)	16	26	23	5	14

Can PRAME immunohistochemistry be used to differentiate sebaceous carcinoma from basal cell carcinoma?

Mohammad Saffari Doost^{1*}, BA, Maria Fernanda Ortega-Springall^{1*}, MD, Summer N. Meyer¹, BS, Nick R. Love¹, MD, PhD, Thomas Konia¹, MD, Maxwell A Fung¹, MD, Maija Kiuru¹, MD, PhD ¹ Department of Dermatology, University of California Davis School of Medicine

Results						
		Exte	ent of St	aining		
0						
1-25%						
26-50%						
51-75%						
76-100%						
Diagnosis	0	4.050/		/		
Sebaceous Carcinoma	0	1-25% 9	5	3 3 3 5 1 - 7 5	% >75% 1	<i>P</i> value <.001
Basal Cell Carcinoma	27	6	2	4	3	<.001


Pattern of Staining

Diagnosis					
		Diffuse	Focal	Patchy	P value
Sebaceous	Carcinoma	6	1	11	<.05
Basal Cell C	arcinoma	12	1	2	<.05
			1	11 2	

Focal


Patchy


Diffuse




Absent	Weak	Moderate	Strong	<i>P</i> value
1	2	2	14	<.001
27	8	5	2	<.001
	1	1 2	1 2 2	1 2 2 14

Localization of Staining










Cytoplasmic

Diagnosis

	Cytoplasmic	Nuclear	Both	P value
Sebaceous Carcinoma	15	3	0	<.001
Basal Cell Carcinoma	0	14	1	<.001

Conclusion

- We found significant differences in the PRAME staining characteristics of BCC and SBC.
- Most BCCs were negative for PRAME negative; those that were positive showed weak, diffuse, and nuclear staining pattern.
- Most SBCs were positive for PRAME and exhibited strong, patchy, and cytoplasmic staining pattern.
- PRAME highlighted the germinative/mature sebocytes.
- Takeaway: PRAME may be a useful additional test in the distinction of sebaceous carcinoma from basal cell carcinoma.



A. Basal cell carcinomaB. Sebaceous carcinoma

Acknowledgements

Dr. Maija Kiuru – Principal Investigator/Mentorship Dr. Maria Fernanda Ortega Springall – Scoring/Manuscript Dr. Maxwell Fung and Dr. Thomas Konia – Collaboration Dr. Nick Love – Discussions/Figures Lan Yu – Histology Summer Meyer – Manuscript

References

- . Doxanas MT, Green WR. Sebaceous Gland Carcinoma: Review of 40 Cases. Archives of Ophthalmology. 1984;102(2):245-249. doi:<u>10.1001/archopht.1984.01040030195025</u>
- Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ. PRAME Expression in Melanocytic Tumors. Am J Surg Pathol. 2018;42(11):1456-1465. doi:10.1097/PAS.0000000000001134
- Donnell SA, LeBlanc RE, Yan S, et al. Comparison of adipophilin and recently introduced PReferentially expressed Antigen in MElanoma immunohistochemistry in the assessment of sebaceous neoplasms: A pilot study. J Cutan Pathol. 2021;48(10): 1252–1261. doi:10.1111/cup.14043
- 4. Ng JKM, Choi PCL, Chow C, et al. PRAME immunostain expression in sebaceous lesions, cutaneous carcinomas and adnexal structures. *Pathology*. 2022;54(6):721-728. doi:10.1016/j.pathol.2022.03.003